Innefu Labs's $30M Series B: India's Sovereign-AI Defense Bet Goes Institutional
India's Innefu Labs raised a $30M Series B in June 2026, led by Singapore's Panthera Growth — a sign global capital is tracking India's national-security AI.
Venture Capital News, Guides & Fund Directory
Venture capital fuels the companies that reshape industries — from AI infrastructure and fintech to healthcare and defense tech. This hub collects our latest analysis on how VC firms evaluate startups, structure deals, and deploy capital across stages and geographies.
What You'll Find Here
- Fund profiles & directories: Stage focus, sector thesis, and check-size context for active investors
- Deal flow analysis: Funding roundups, mega-rounds, and emerging-manager activity
- Founder playbooks: Pitch decks, term sheets, warm intros, and fundraising strategy
- Market intelligence: Sector trends, valuation shifts, and LP allocation patterns
Browse the articles below to research investors, understand deal dynamics, and build a sharper fundraising strategy.
Related Articles (847 articles)
-
-
Factorial's $150M Series D at $2.5B: AI-Native Workforce Operations
Barcelona's Factorial raised $150M Series D at a $2.5B valuation in June 2026, expanding from HR software into AI-powered workforce operations across Europe.
-
NYC VC Fund Launch: Blue Cloud Ventures Closes Fund V, Crosses $1B AUM
New York-based Blue Cloud Ventures announced the final close of Fund V on June 2, 2026, bringing total AUM above $1 billion for enterprise SaaS and AI growth investing.
-
Wordsmith's $70M Series B: Edinburgh's Legal AI Hits $100M Total
Edinburgh legal-AI startup Wordsmith raised a $70M Series B in June 2026, backed by Highland Europe and Index Ventures, reaching $100M in total funding.
-
Semble's £30M Series C: Modern Software for Healthcare Providers
UK healthcare-tech company Semble raised a £30M Series C led by Revaia in June 2026, scaling its practice-management platform for clinicians.
-
Ona Therapeutics's $86.6M Series B: Barcelona's ADC Cancer Bet
Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.